sj.png

SJ (Sung Joo) LEE, Ph.D.

Sung Joo Lee is the chief executive officer and founder of Orum Therapeutics. He has initiated and led many research and drug discovery efforts, uniting diverse internal and external scientific teams.  Before founding Orum in 2016, Sung Joo spent five years at LG Life Sciences and then more than six years at Sanofi; first as the Korea R&D leader and then as head of research for Asia Pacific R&D. In the latter role, he initiated and led projects around a virtual biotech model to co-invent drugs with biotech and academia teams based in Korea, China, and Japan. He also oversaw collaborations with various partners in the region, including the Institute Pasteur, Asan Medical Center, and KAIST.  Throughout his career, Sung Joo has worked to improve the therapeutic landscape for various diseases, including hepatitis B, hepatocellular carcinoma (HCC), diabetes, and Alzheimer’s disease. Sung Joo earned a Ph.D. in biophysics from the University of California, Berkeley.

 
 
park.png

Peter U. Park, Ph.D.

Peter is the Chief Scientific Officer at Orum Therapeutics and is based in Cambridge, MA. Peter brings over 17 years of scientific management experience in targeted therapeutics in oncology.  At Orum, he is currently overseeing the discovery and development of novel therapeutics based on a cell-penetrating antibody platform. Prior to joining Orum, he served as Vice President of Oncology Research at Bicycle Therapeutics, where he developed novel therapeutics using bicyclic peptides to activate T cell costimulatory pathways and  deliver cytotoxic drug or innate immune activators. Peter has held a variety of roles in oncology drug discovery and development, including Vice President of Biology at Mersana Therapeutics, Senior Director of Discovery Research at ImmunoGen and founder of startup companies. Peter co-invented and developed numerous clinical candidates, including Isatuximab, a monoclonal antibody designed for the treatment of multiple myeloma—currently in Phase 3 trials with Sanofi. Peter has a B.S. and a Ph.D. in Biology from MIT.


 
 
K.png

K Ki Hwan Chang, Ph.D.

K Ki Hwan Chang, Ph.D. serves as Research Director for Orum Therapeutics and is based in Daejeon, Korea. K is regarded as an expert in antibodies and phage display. At Orum, K directs research into antibodies engineered to specifically target different cell-surface receptors to enhance binding to specific tissues. Prior to joining Orum, K served as a research scientist and team leader, Antibody Engineering Team, for CJ HealthCare, where he led antibody discovery research for a novel immuno-cancer therapy. Prior to that, K worked in antibody engineering for GC Pharma and gene therapy at the Samyang Genex Corporation. K earned his bachelor’s degree in microbiology from Chungbuk National University and a master’s degree in molecular virology and biochemistry from Yonsei University. He studied phage display of proteins and peptides at Cold Spring Harbor Laboratory before earning his Ph.D. in molecular virology and biochemistry from Yonsei University in 2013. His research on anti-EGFR antibody led to Phase 1 trials in cancer, and anti-HBV antibody led to Phase 2 trials in liver transplantation and phase 1 trials in chronic hepatitis B. K holds 15 patents and has published eight peer-reviewed journal articles.

 
 
yskim.png

Yong-Sung KIM, Ph.D.

Yong-Sung Kim is a scientific co-founder of Orum Therapeutics and a pioneer in antibody engineering for therapeutic applications. He has published more than 95 peer-reviewed articles and holds multiple domestic and international patents. To date, Yong-Sung has transferred four antibody-related technologies to companies in Korea and the United States. Since 2004, Yong-Sung has been a professor in the department of molecular science and technology at Ajou University (Suwon, Korea), including a one-year sabbatical at Genentech. His academic work has focused on the development of platform technology for next generation therapeutic antibodies, including cellular cytosol-penetrating antibodies and heterodimeric Fc-based bispecific antibodies. His group also deploys using yeast surface display technology for advanced antibody and protein engineering. Yong-Sung obtained a master’s degree in biotechnology from KAIST (Daejeon, Korea) and a Ph.D. in pharmaceutical sciences from the University of Colorado in the United States. This was followed by a post-doctoral position in the laboratory of Professor K. Dane Wittrup at MIT (Cambridge, USA).